Summary of the predictors of TB treatment interruption
| Predictors | Studies | Participants | Odds ratio (95% CI) | I2 | Sensitivity analysis |
| Male gender | 37 | 327 282 | 1.38 (1.26 to 1.51) | 79% | Remain significant 1.46 (1.30, 1.63) |
| Southern Asia | 14 | 6297 | 1.51 (1.16 to 1.95) | 62% | Remain significant 1.34 (1.06, 1.70) |
| Eastern Asia | 13 | 164 757 | 1.19 (1.06 to 1.32) | 67% | Remain significant 1.26 (1.05, 1.51) |
| South East Asia | 3 | 536 | 1.03 (0.51 to 2.08) | 49% | Not estimated |
| Western Asia | 4 | 12 298 | 2.29 (1.90 to 2.74) | 0% | No changes |
| Central Asia | 3 | 143 394 | 1.46 (1.20 to 1.77) | 90% | No changes |
| Age ≥60 or 65 | 9 | 156 679 | 1.15 (0.89 to 1.49) | 75% | No significant changes 1.07 (0.85, 1.35) |
| Age ≥60 | 5 | 17 281 | 1.13 (0.83 to 1.55) | 93% | No significant changes 1.17 (0.83, 1.65) |
| Age ≥65 | 4 | 139 398 | 1.09 (0.59 to 2.02) | 87% | No significant changes 0.92 (0.68, 1.24) |
| Single/widowed/divorced | 15 | 5293 | 1.23 (0.91 to 1.67) | 77% | No significant changes 1.09 (0.70, 1.70) |
| Southern Asia | 6 | 1855 | 1.09 (0.59 to 2.01) | 84% | No significant changes 1.11 (0.54, 2.30) |
| Eastern Asia | 6 | 2336 | 1.24 (0.80 to 1.93) | 78% | No significant changes 0.79 (0.38, 1.67) |
| South East Asia | 1 | 249 | 2.21 (0.90 to 5.39) | NA | Not estimated |
| Western Asia | 2 | 853 | 1.41 (0.78 to 2.58) | 56% | No changes |
| Illiterate | 8 | 2269 | 1.58 (0.88 to 2.84) | 84% | No significant changes 1.64 (0.61, 4.41) |
| Employment | 9 | 2999 | 1.43 (1.11 to 1.84) | 23% | Remain significant 1.59 (1.12, 2.28) |
| Urban residence | 8 | 272 906 | 0.94 (0.70 to 1.26) | 98% | No significant changes 0.98 (0.72, 1.32) |
| Alcohol intake | 13 | 3254 | 2.24 (1.58 to 3.18) | 58% | Remain significant 2.46 (1.62, 3.75) |
| Smoking | 14 | 4092 | 2.74 (1.98 to 3.78) | 66% | Remain significant 2.72 (1.77, 4.17) |
| HIV positive | 5 | 124 824 | 1.50 (1.15 to 1.96) | 1% | No changes |
| Diabetes | 7 | 3265 | 1.21 (0.77 to 1.90) | 75% | No significant changes 1.14 (0.67, 1.93) |
| Previously treated cases | 13 | 142 034 | 1.77 (1.39 to 2.26) | 92% | Remain significant 1.83 (1.34, 2.51) |
| Southern Asia | 3 | 2418 | 1.46 (0.56 to 3.76) | 86% | No significant changes 0.98 (0.69, 1.39) |
| Eastern Asia | 5 | 19 594 | 1.33 (0.93 to 1.90) | 88% | Significant changes 1.52 (1.32, 1.74) |
| Western Asia | 3 | 11 862 | 3.70(2.34 to 5.85) | 35% | No changes |
| Central Asia | 2 | 108 160 | 2.14 (1.70 to 2.71) | 35% | No changes |
| PTB | 12 | 193 863 | 1.18 (0.98 to 1.42) | 81% | No significant changes 1.09 (0.91, 1.29) |
| Positive sputum smear | 12 | 215 903 | 0.95 (0.78 to 1.16) | 95% | No significant changes 1.04 (0.83, 1.31) |
| Adverse drug reaction | 9 | 2760 | 2.01 (1.20 to 3.34) | 81% | Remain significant 2.18 (1.02, 4.69) |
PTB, pulmonary tuberculosis; TB, tuberculosis.